NL-OMON20720尚未招募不适用
International Multicenter Phase I trial of Hydroxyurea in Combination with Dose-Intense Temozolomide in Recurrent Glioblastoma.
VU University Medical Center0 个研究点目标入组 35 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Participants must have histologically or cytologically confirmed glioblastoma multiforme
- •2. Patients may have had any number of prior therapies for glioblastoma. Patients must be at least 28 days from any investigational agent, 28 days from prior cytotoxic therapy (except 23 days from prior temozolomide, 14 days from vincristine, 42 days from nitrosoureas, 21 days from procarbazine administration), and 7 days for patients who received metronomic chemotherapy or non-cytotoxic agents, e.g., interferon, tamoxifen, thalidomide, cis-retinoic acid, etc.
排除标准
- •1. Participants who are receiving any other investigational agents or devices in investigation for glioblastoma.
- •2. Patients must not have been previously treated with an anti-VEGF inhibitor.
研究者
相似试验
已完成
不适用
International Multicenter Phase I trial of Hydroxyurea in Combination with Dose-Intense Temozolomide in Recurrent Glioblastoma.High grade glioma10029211brain tumorNL-OMON50467Vrije Universiteit Medisch Centrum49
招募中
不适用
Open label trial for efficacy and safety of Hydroxychloroquine for systemic lupus erythematosusJPRN-UMIN000012478Department of Internal Medicine, Teikyo University School of Medicine10
已完成
3 期
Hydroxychloroquine prophylaxis in preventing the severe forms of Covid-19IRCT20200421047153N1Islamic Azad University1,000
进行中（未招募）
1 期
Pilot trial on early treatment with hydroxychloroquine in patients withCOVID-19 who do not have hospital admission at diagnosis.Patients diagnosed with COVID-19, with positive PCR for SARS-CoV-2, without criteria for hospital admission.MedDRA version: 23.0Level: LLTClassification code 10084401Term: COVID-19 respiratory infectionSystem Organ Class: 100000004862EUCTR2020-002449-41-ESANTONIO ANTELA LOPEZ340
招募中
3 期
Investigating the efficacy and safety of Hydroxychloroquine nasal spray in controlling the symptoms of patients with COVID-19IRCT20080901001165N51Sina Darou Laboratories Company80